Last updated 13 days ago

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

308 patients around the world
Available in Argentina, United States
Merck Sharp & Dohme LLC
2Research sites
308Patients around the world

This study is for people with

Bladder Cancer
Non-muscle-invasive bladder cancer

Requirements for the patient

From 18 Years
All Gender

Medical requirements

Is an individual whose most recent TURBT was performed within 12 weeks before randomization/allocation and showed BICR-confirmed high-risk NMIBC histology.
BCG Arms:
Has high-risk non-muscle invasive (HG Ta, T1, and/or CIS) UC of the bladder.
Is BCG-naïve defined as either having never received BCG or having received BCG more than 2 years before high-risk NMIBC recurrence. Recurrence must be at least 24 months from the last exposure to BCG with evidence of complete response during the 2-year period post BCG.
V940 Monotherapy Arm:
Has CIS +/-papillary non-muscle invasive UC of the bladder.
Is ineligible for, or refusing, any IVESIC therapy.
Is either BCG-naïve (as defined above) or BCG-exposed but did not receive protocol-specified minimum dosing of BCG and experienced recurrence of high-risk NMIBC within 2 years of the last dose of BCG.
Human immunodeficiency virus (HIV)-infected individuals must have well controlled HIV on antiretroviral therapy (ART).
Has a history of or concurrent locally-advanced (ie, T2, T3, T4) or metastatic UC.
Has concurrent extravesical (ie, urethra, ureter, renal pelvis) non-muscle invasive UC or a history of extravesical non-muscle invasive UC that recurred within the last 2 years, with certain exceptions.
Has a known additional malignancy that is progressing or has required active treatment within the last 3 years.
Has had a myocardial infarction within 6 months of randomization/allocation.
Has received any systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.
Has received prior treatment with a cancer vaccine.
Has immunodeficiency or is receiving chronic systemic steroid therapy.
Has active autoimmune disease that has required systemic treatment in the last 2 years.
Has any contraindication to IV contrast and gadolinium or is otherwise unable to have imaging with either computerized tomography urogram (CTU) or Magnetic resonance urography (MRU).
BCG Arms:
Has current active tuberculosis.
Has a known history of HIV infection.
V940 Monotherapy Arm:: HIV-infected individuals with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.

Sites

Instituto de Investigaciones Clínicas Mar del Plata
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Av. Colón 3456, Mar del Plata, Buenos Aires
Hospital Asociación de Beneficencia Hospital Sirio Libanes - CABA, Buenos Aires
Hospital Asociación de Beneficencia Hospital Sirio Libanes - CABA, Buenos Aires
Recruiting
Campana 4658, CABA, Buenos Aires
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy